Earnings Call Summary | Jaguar Health(JAGX.US) Q1 2024 Earnings Conference
Earnings Call Summary | Jaguar Health(JAGX.US) Q1 2024 Earnings Conference
The following is a summary of the Jaguar Health, Inc. (JAGX) Q1 2024 Earnings Call Transcript:
以下是捷豹健康公司（JAGX）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Jaguar Health reported a Q1 2024 net revenue of approximately $2.4 million, signaling a 20% increase year over year and a 4% increase quarter over quarter.
The company managed to reduce its operational loss to $8.2 million in Q1 2024 from $9.9 million in Q1 2023.
The net loss attributable to common shareholders also decreased to $9.2 million in Q1 2024, down from the $12.2 million reported in Q1 2023.
捷豹健康報告稱，2024年第一季度淨收入約爲240萬美元，同比增長20％，同比增長4％。
該公司設法將其運營虧損從2023年第一季度的990萬美元減少到2024年第一季度的820萬美元。
歸屬於普通股股東的淨虧損也從2023年第一季度公佈的1,220萬美元降至2024年第一季度920萬美元。
Business Progress:
業務進展：
Jaguar Health is expectantly waiting for the results from the OnTarget trial involving the drug Crofelemer for cancer therapy-related diarrhea.
The company is broadening its commercial footprint beyond HIV supportive care into cancer-related supportive care and will introduce the FDA-approved oral mucositis prescription Gelclair for the United States market.
They are also planning for early patient access for Crofelemer for intestinal failure in Europe by 2025.
The company is actively engaging with the oncology community through congresses and meetings, showcasing their commitment towards supporting cancer care.
捷豹健康期待着OnTarget試驗的結果，該試驗涉及Crofelemer用於治療癌症療法相關腹瀉的藥物。
該公司正在將其商業版圖從HIV支持性護理擴展到與癌症相關的支持性護理，並將向美國市場推出經FDA批准的口服粘膜炎處方Gelclair。
他們還計劃到2025年讓歐洲的腸衰竭患者儘早獲得Crofelemer的治療。
該公司正在通過大會和會議積極與腫瘤學界互動，展示他們對支持癌症治療的承諾。
More details: Jaguar Health IR
更多詳情： 捷豹健康 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。